That is according to data from a phase 1b clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and colleagues at centers around the world. The work appears in the current online edition of the Journal of Clinical Oncology (doi: 10.1200/JCO.2017.72.5069).
Janice M. Mehnert, MD, director of the Phase 1/Investigational Therapeutics Program at Rutgers Cancer Institute, associate professor of medicine at Rutgers Robert Wood Johnson Medical School, and senior director on the work said, “Immunotherapy drugs put the body’s natural defenses back to work by targeting the PD-L1 protein and PD-1 receptor and blocking their ability to prevent T cells from destroying cancer cells.”
From March 2014 to May 2015, 157 patients with extensive-stage SCLC were screened from multiple international sites.
Of that number, 24 patients with tumors having a large presence of the PD-L1 protein who were previously treated with platinum-based therapy were enrolled in the trial.
Participants received 10mg of pembrolizumab every two weeks for 24 months or until confirmed disease progression or unacceptable toxicity. Safety, tolerability and response were assessed every eight weeks for the first six months and every 12 weeks thereafter. Median follow-up duration was 9.8 months.
Of the evaluable patients, one had a complete response and seven had partial responses for an overall response rate of 33 percent. Sixteen patients (67 percent) experienced treatment related adverse events with the most common being joint pain, rash and lack of energy.
Two patients experienced grade three to five adverse events including one with elevated bilirubin. Another patient experienced weakness, grade-five colitis and reduced blood flow to the intestines.
Dr. Mehnert noted, “Our findings show the safety of pembrolizumab in SCLC is consistent with the known safety profile in other tumor types. These results also show pembrolizumab demonstrates promising anti-tumor activity in SCLC patients who received prior treatment and have a large presence of the PD-L1 protein in their tumor.”
Building on the findings of this study, a number of clinical trials have been launched at Rutgers Cancer Institute and elsewhere that aim to more accurately define which SCLC patients are more likely to respond to pembrolizumab.
Others aim to explore the safety and efficacy of pembrolizumab when combined with other modes of treatment including chemotherapy, radiation and other immunotherapy regimens.
Along with Mehnert, other investigators on the study include Patrick A. Ott, Dana-Farber Cancer Institute; Elena Elez, Vall d’Hebron Institute of Oncology (Spain); Sandrine Hiret, ICO René Gaudcheau (France); Dong-Wan Kim, Seoul National University Hospital (Republic of Korea); Anne Morosky, Sanatan Saraf and Bilal Piperdi, all Merck & Co., Inc. (Kenilworth, New Jersey).
This work was supported by Merck & Co., Inc., Kenilworth, New Jersey.
About Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey (www.cinj.org) is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center. As part of Rutgers, The State University of New Jersey, Rutgers Cancer Institute is dedicated to improving the detection, treatment and care of patients with cancer, and to serving as an education resource for cancer prevention both at its flagship New Brunswick location and at its Newark campus at Rutgers Cancer Institute of New Jersey at University Hospital.
Physician-scientists across Rutgers Cancer Institute also engage in translational research, transforming their laboratory discoveries into clinical practice that supports patients on both campuses.
To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving. Follow us on Facebook at www.facebook.com/TheCINJ.